Lv1
70 积分 2025-08-12 加入
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
1个月前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
2个月前
已完结
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
2个月前
已完结
Drug-tolerant persister cells in cancer: the cutting edges and future directions
2个月前
已完结
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
3个月前
已完结
Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC
3个月前
已关闭
Overall survival assessment in cancer drug trials: a luxury or a necessity?
4个月前
已关闭
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
4个月前
已完结
The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally
5个月前
已完结
SLC40A1+ macrophages contribute to the immunosuppressive tumor microenvironment in EGFR-mutated lung cancer
5个月前
已完结
皖公网安备34019202002308
